Phloridzin exhibits high specificity for GLUT2, particularly in triple‐negative breast cancer (TNBC), where it blocks glucose transport, disrupts energy metabolism, and reduces tumor growth (Wu et al. 2018). Here, SLC2A2 is linked to neoplasm.